Karanika S et al.Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.Cell Rep 18:1970-1981 (2017).
Massey AJ Tumour growth environment modulates Chk1 signalling pathways and Chk1 inhibitor sensitivity.Sci Rep 6:35874 (2016).
Bryant C et al.Inhibition of the checkpoint kinase Chk1 induces DNA damage and cell death in human Leukemia and Lymphoma cells.Mol Cancer 13:147 (2014).
Rawlinson R & Massey AJ ?H2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments.BMC Cancer 14:483 (2014).
Bryant C et al.Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.BMC Cancer 14:570 (2014).
Huh J & Piwnica-Worms H CRL4(CDT2) targets CHK1 for PCNA-independent destruction.Mol Cell Biol 33:213-26 (2013).
Ma CX et al.A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.Breast Cancer Res Treat 137:483-92 (2013).
Ma CX et al.Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.J Clin Invest 122:1541-52 (2012).